Journal
CELL STEM CELL
Volume 30, Issue 6, Pages 748-749Publisher
CELL PRESS
DOI: 10.1016/j.stem.2023.05.008
Keywords
-
Categories
Ask authors/readers for more resources
The lack of pre-clinical models and biomarkers has made clinical trials in amyotrophic lateral sclerosis (ALS) challenging. Morimoto et al. used induced pluripotent stem cell (iPSC)-derived motor neurons from ALS patients to study the therapeutic mechanisms of ropinirole in a clinical trial and identify responders.
Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
